QuantCapitol. Congressional Trading Intelligence

Updated 2026-11-06 00:24 UTC · Public disclosure record

EXCTICKER

Exelon Corp.

VERY BULLISH stock

Congress has disclosed 12 buys and 7 sells of EXC (Exelon Corp.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.

Activity Congressional Activity

12
Buy
7
Sell
+5
Net
10
Active politicians

Round-trip watch Still on the books

Members who disclosed buying EXC and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.

MemberEntry (last buy)Entry priceNowvs entryStatus
Marjorie Taylor Greene 2025-10-15 $46.14 $46.16 +0.1% ↩ near entry

Price as of 2026-10-30. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).

Price & congressional trades
Buy Sell

Fundamentals · FY2026 Valuation

Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for —. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.

P/E
17.0
no sector median
how it's calculated
P/E = price ÷ earnings per share
$46.16 ÷ $2.72 = 17.0
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
P/B
1.61
no sector median
how it's calculated
P/B = price ÷ book value per share
$46.16 ÷ $28.65 = 1.61
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
EV/EBITDA
10.84
no sector median
how it's calculated
EV/EBITDA = (market cap + net debt) ÷ EBITDA
($47.2B + $48.8B net debt) ÷ $8.9B = $96.0B ÷ $8.9B = 10.84
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.

20 trades Recent Congressional Trades

Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.

PoliticianChamberTypeOwnerDateDisclosure lagPrice move
in that
window
AmountScoreSource
Lisa McClain House SELL Spouse · Charles Schwab 401K > Schwab 893 2025-10-31 1 days 0.0% $1K–$15K
0.1% of NW
7.8 ↗ filing
Lisa McClain House SELL Spouse · Charles Schwab Brokerage Account 924 2025-10-30 2 days -2.0% $1K–$15K
0.1% of NW
28.1 ↗ filing
Lisa McClain House BUY Spouse · Charles Schwab 401K > Schwab 893 2025-10-30 2 days -2.0% $1K–$15K
0.1% of NW
33.4 ↗ filing
Marjorie Taylor Greene House BUY Self 2025-10-15 1 days -1.0% $1K–$15K 53.3 ↗ filing
Marjorie Taylor Greene House BUY Self 2025-08-28 1 days -0.2% $15K–$50K 92.1 ↗ filing
Lisa McClain House BUY Spouse · Charles Schwab Brokerage Account 924 2025-06-17 57 days +7.6% $1K–$15K
0.1% of NW
63.6 ↗ filing
Mary Gay Scanlon House SELL Joint · Brokerage C: Partial sale- remaining shares gifted to family member 2023-05-23 1 days — $15K–$50K
0.3% of NW
66.9 ↗ filing
Mary Gay Scanlon House EXCHANGE Joint · Brokerage 2022-02-04 201 days — $15K–$50K
0.3% of NW
96.3 ↗ filing
Gilbert Cisneros House BUY Self 2020-03-18 28 days — $1K–$15K
0.1% of NW
86.9 ↗ filing
Susan Davis House BUY Spouse 2020-03-16 2 days — $1K–$15K 52.4 ↗ filing
Bill Flores House BUY Self 2019-05-08 28 days — $1K–$15K 40.5 ↗ filing
Bill Flores House BUY Self 2019-03-25 9 days — $1K–$15K 75.9 ↗ filing
John Rutherford House SELL Self 2018-06-20 10 days — $1K–$15K
0.8% of NW
40.5 ↗ filing
Susan Davis House BUY Spouse 2018-03-07 2 days — $1K–$15K 75.9 ↗ filing
John Rutherford House BUY Self 2017-10-25 6 days — $1K–$15K
0.8% of NW
75.9 ↗ filing
Katherine Clark House SELL Self 2015-11-19 14 days — $1K–$15K
0.1% of NW
40.5 ↗ filing
Thomas MacArthur House SELL Self 2015-05-27 5 days — $1K–$15K 40.5 ↗ filing
Thomas MacArthur House BUY Self 2015-04-17 14 days — $1K–$15K 75.9 ↗ filing
Katherine Clark House BUY Self 2014-12-01 85 days — $1K–$15K
0.1% of NW
75.9 ↗ filing
Pete Sessions House SELL Spouse 2013-11-11 0 days — $1K–$15K
0.2% of NW
75.9 ↗ filing

Corporate insiders · SEC Form 4 Insider Activity

What the company's own officers and directors did in EXC — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →

0
Congress trades with insider convergence
0
…with insider divergence
3
Insider open-market trades

Of the congressional trades in EXC, 0 coincided with corporate insiders moving the same way within 60 days, and 0 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.

DateInsiderRoleTypeSizeSource
2025-02-03 Glockner David Other SELL $245K ↗ EDGAR
2025-02-03 Honorable Colette D Other SELL $59K ↗ EDGAR
2023-03-17 Khouzami Carim V C-suite SELL $250K ↗ EDGAR

Combined timeline — Congress & insiders

Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.

DateWhoTypeSize
Congress 2025-10-31 Lisa McClain SELL $1K–$15K
Congress 2025-10-30 Lisa McClain SELL $1K–$15K
Congress 2025-10-30 Lisa McClain BUY $1K–$15K
Congress 2025-10-15 Marjorie Taylor Greene BUY $1K–$15K
Congress 2025-08-28 Marjorie Taylor Greene BUY $15K–$50K
Congress 2025-06-17 Lisa McClain BUY $1K–$15K
◆ insider 2025-02-03 Glockner David Other SELL $245K
◆ insider 2025-02-03 Honorable Colette D Other SELL $59K
Congress 2023-05-23 Mary Gay Scanlon SELL $15K–$50K
◆ insider 2023-03-17 Khouzami Carim V C-suite SELL $250K
Congress 2022-02-04 Mary Gay Scanlon EXCHANGE $15K–$50K
Congress 2020-03-18 Gilbert Cisneros BUY $1K–$15K
Congress 2020-03-16 Susan Davis BUY $1K–$15K
Congress 2019-05-08 Bill Flores BUY $1K–$15K
Congress 2019-03-25 Bill Flores BUY $1K–$15K
Congress 2018-06-20 John Rutherford SELL $1K–$15K
Congress 2018-03-07 Susan Davis BUY $1K–$15K
Congress 2017-10-25 John Rutherford BUY $1K–$15K
Congress 2015-11-19 Katherine Clark SELL $1K–$15K
Congress 2015-05-27 Thomas MacArthur SELL $1K–$15K
Congress 2015-04-17 Thomas MacArthur BUY $1K–$15K
Congress 2014-12-01 Katherine Clark BUY $1K–$15K
Congress 2013-11-11 Pete Sessions SELL $1K–$15K

FAQ Common questions

How much has Congress traded EXC?

12 disclosed buys and 7 sells of EXC (Exelon Corp.) appear in official congressional financial disclosures.

Is it legal for members of Congress to trade EXC?

Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.

Where does this data come from?

Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.

About this data. Sourced from official House Clerk and Senate eFD financial disclosures (Senate via a maintained community mirror — see project documentation). Transaction amounts are reported as ranges, not exact figures. Interest scores, consensus labels, and backtested performance are proprietary analytical calculations based on public data and are not investment advice. Backtested performance is a hypothetical simulation, not actual portfolio performance.